Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Protagonist Therapeutics (PTGX) Receivables - Other (2017 - 2025)

Protagonist Therapeutics' Receivables - Other history spans 9 years, with the latest figure at $4.4 million for Q4 2025.

  • For Q4 2025, Receivables - Other rose 34.64% year-over-year to $4.4 million; the TTM value through Dec 2025 reached $4.4 million, up 34.64%, while the annual FY2025 figure was $4.4 million, 34.64% up from the prior year.
  • Receivables - Other for Q4 2025 was $4.4 million at Protagonist Therapeutics, up from $583000.0 in the prior quarter.
  • Across five years, Receivables - Other topped out at $25.2 million in Q1 2022 and bottomed at $10000.0 in Q4 2022.
  • The 5-year median for Receivables - Other is $2.1 million (2021), against an average of $6.0 million.
  • The largest YoY upside for Receivables - Other was 2460.0% in 2023 against a maximum downside of 99.8% in 2023.
  • A 5-year view of Receivables - Other shows it stood at $1.6 million in 2021, then crashed by 99.36% to $10000.0 in 2022, then surged by 2460.0% to $256000.0 in 2023, then skyrocketed by 1166.41% to $3.2 million in 2024, then surged by 34.64% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Receivables - Other are $4.4 million (Q4 2025), $583000.0 (Q3 2025), and $23.4 million (Q2 2025).